Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abuse-deterrent Immediate Release Oral Ketamine Capsules for Treatment Resistant Bipolar Depression: A Phase 2A, Randomised, Double-blind, Placebo-controlled Study

Next Previous
Trial Profile

Abuse-deterrent Immediate Release Oral Ketamine Capsules for Treatment Resistant Bipolar Depression: A Phase 2A, Randomised, Double-blind, Placebo-controlled Study

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Bipolar depression; Treatment-resistant depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Neurocentrx Pharma

Most Recent Events

  • 23 Sep 2025 According to Neurocentrx Pharma media release, company plans to initiate the trial in first quarter of 2026
  • 14 Dec 2023 New trial record
  • 24 Oct 2023 According to Neurocentrx Pharma media release, In the first half of 2024, Neurocentrx plans to initiate this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top